This page respects the original work's rights terms and independently introduces its bibliography, abstract, main results, and limitations. It is not a full translation.
About this resource
This is not a full-text translation of the original paper. It is an independently organized detailed introduction based on public information, covering the peptides at issue, types of evidence, inference to humans, and remaining uncertainty. The source is a review and commentary that gathers mainly animal, cell, and receptor research on individual peptides identified in Phyllomedusa bicolor secretion and considers whether their pharmacology could correspond to human responses observed in kambô rituals.
Evidence on isolated peptides is kept separate from evidence on whole secretion. A result in which a synthetic peptide injures cultured cells, changes an animal’s blood pressure, or binds a particular receptor does not by itself demonstrate the efficacy or safety of a kambô ritual. In people, multiple constituents are absorbed at the same time, in unknown amounts, through burn wounds.
Study design
The paper is neither a systematic review nor a clinical trial. Drawing on existing biological and pharmacologic literature, the authors organized the effects of linear peptides in the secretion and considered how animal and in vitro information might apply to human ritual responses. They identify the near absence of research directly measuring the simultaneous effects of whole secretion in humans as a central evidence gap.
In previously reported dried secretion, bioactive peptides were estimated at approximately 7.5% by weight. However, the number of mg absorbed per point in an individual ritual, the skin barrier, variation among animals, and changes through drying and storage have not been standardized. A content estimate is therefore not an established clinical dose.
Content
Phyllocaerulein is discussed in relation to gastrointestinal smooth muscle and gastric and pancreatic secretion; phyllomedusin in relation to tachykinin-like vascular, smooth-muscle, and exocrine activity; phyllokinin in relation to vasodilation involving bradykinin receptors; and sauvagine in relation to circulatory and stress responses through the CRF system. These actions may be pharmacologically consistent with nausea, vomiting, abdominal responses, flushing, reduced blood pressure, and tachycardia immediately after a ritual, but they do not establish a single cause for each symptom.
Dermorphin and deltorphin are known for high affinity at μ- and δ-opioid receptors, respectively. Even when potent activity is reported for an isolated peptide, its concentration in whole secretion, passage from the periphery to the central nervous system, and interactions with other constituents remain unknown. Direct claims about human analgesia or treatment effects therefore cannot be made.
For dermaseptins and adenoregulin, the paper introduces antimicrobial effects, membrane activity, and in vitro activity against cancer cells. These are findings about candidate molecules, not a basis for applying whole secretion to people with infection or cancer. Activity against cells also requires simultaneous study of toxicity to normal tissue and stability in the body.
Results
The review’s integrated view was that multiple peptides could explain some gastrointestinal, circulatory, endocrine, and nervous-system responses observed after kambô. At the same time, synergistic and antagonistic effects among all constituents remain hypotheses, and there is insufficient direct human evidence on pharmacokinetics, actual absorption, receptor occupancy, and individual variation.
The authors also discuss possibilities for clinical research, but these are proposals for future investigation, not confirmation of a present treatment effect. Positive testimonials after ritual, basic activity of isolated peptides, and medical efficacy of whole secretion are 3 different categories of evidence.
Limitations
The review does not quantify its search and selection procedures in a PRISMA-style process and narratively connects heterogeneous basic research. Many effects were observed in other animal species, excised tissues, cultured cells, or synthetic peptides rather than through the same route and mixture used in a kambô ritual. Human research on whole secretion is sparse, and claims of synergy are based more on inference than direct measurement.
A professional relationship with kambô practice is reported for 1 author, so conflicts of interest and perspective need to be considered in interpretation. A “possibility” in the review must not be expanded into an established indication, recommendation, or dose.
Safety
The pharmacologic activity of these peptides can itself create hazards including reduced blood pressure, tachycardia, changes in vascular permeability, intense vomiting, and endocrine or electrolyte changes. If multiple constituents act simultaneously, adverse reactions that amplify each other must be considered alongside desired effects.
The study did not establish safe participants, point count, amount administered, contraindications, or emergency response. Academic interest in an individual peptide cannot be converted into self-administration of unstandardized whole secretion.
Source and rights
Original source: Thompson C, Williams ML. Review of the physiological effects of Phyllomedusa bicolor skin secretion peptides on humans receiving Kambô. Toxicology Research and Application. 2022;6:1–13. DOI 10.1177/23978473221085746.
The original article is published under Creative Commons Attribution-NonCommercial 4.0 (CC BY-NC 4.0). To avoid uncertainty around conditions including commercial use, this page is an independent detailed introduction rather than a translation and does not reproduce the source’s tables, figures, or prose.